CEBPA抗体

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Western blot analysis using CEBPA mouse mAb against THP-1 (1)cell lysate.    

  
  

•  

   

     Flow cytometric analysis of HeLa cells using CEBPA mouse mAb (green) and negative control (red).    

  
  

The CEBPA (CCAAT/enhancer-binding protein alpha) antibody is a crucial tool in molecular and cancer research, targeting the CEBPA transcription factor involved in cellular differentiation, metabolism, and immune responses. CEBPA regulates genes critical for granulocyte and adipocyte development, glucose homeostasis, and cell cycle control. Its role in hematopoiesis makes it a focus in acute myeloid leukemia (AML) studies, where mutations or dysregulation of CEBPA are linked to leukemogenesis.

CEBPA antibodies are widely used in techniques like Western blotting, immunohistochemistry, and flow cytometry to detect protein expression, localization, and mutations. These antibodies help identify CEBPA’s dual isoforms (p42 and p30), with isoform imbalances often associated with AML prognosis. Researchers also employ them to study CEBPA’s interactions with other proteins or DNA, shedding light on its regulatory networks.

Commercial CEBPA antibodies are typically raised in rabbits or mice, with validation in specific applications. Their specificity is critical, as cross-reactivity with other CEBP family members (e.g., CEBPB or CEBPD) can confound results. Clinically, CEBPA antibody-based assays aid in diagnosing AML subtypes and guiding therapeutic strategies, particularly for patients with CEBPA mutations. Ongoing research continues to explore its role in solid tumors and metabolic disorders, underscoring its versatility in biomedical studies.